Established in 2001 by academic researchers, The Assessment Group is now an independent company delivering high-quality assessment services for a slew of pharmaceutical and biotech companies, and many more institutions involved in the healthcare industry. The firm’s core business is to prepare comprehensive practice pattern evaluations for healthcare sector marketing initiatives.
The Assessment Group’s offerings identify and evaluate the impact of promotional activities, which have influence on management and treatment decisions. The Assessment Group is recognized for the provisioning of high-quality, objective and efficient assessments. It elaborates and offers both custom-built and ready-made reports. The firm equips clients with the unparalleled solution focused impact metrics.
The reports prepared by The Assessment Group uncover essential data on the modern physician practice patterns, provide detailed discussions of various clinical decisions along with comprehensive analyses of the forces influencing them, examine key challenges to patient care, and unveil relevant information required to elaborate efficient market strategies leading to fruitful results.
Publications found:
22
Sort by:
US Market Changes in the Treatment of Advanced Prostate Cancer
US$ 2,900.00
Progressively unfolding patient case scenarios were presented to 151 U.S. oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence ...
September 2012
30 pages
US Market Changes in the Treatment of Advanced Melanoma
US$ 2,900.00
... regimen choices, factors that influence their decisions, barriers to optimal patient care and confidence in patient treatment. This report identifies market changes based on a comparison of physician practice patterns from 2011 and 2012 and provides actionable data for developing marketing strategies.
September 2012
31 pages
US Market Changes in the Treatment of Advanced Breast Cancer
US$ 2,900.00
... of treatment regimens, factors that influenced their decisions, barriers to optimal patient treatment and confidence in treatment and management of patients. This survey was conducted in 2011 and 2012 to determine trends across time and changes in practice patterns in the management of advanced breast cancer.
September 2012
34 pages
US Market Changes in the Treatment of Advanced Lung Cancer
US$ 2,900.00
The purpose of this study is to examine changes in the market for therapeutics used in the treatment of advanced lung cancer by examining longitudinal practice patterns of oncologists. Progressively unfolding patient case scenarios were presented to 152 U.S. oncologists for their responses to open-ended ...
September 2012
39 pages
US Market Changes in the Treatment of Non-Hodgkin's Lymphoma
US$ 2,900.00
... factors that influenced their decisions, barriers to optimal patient treatment and confidence in treatment and management of patients. This survey was conducted in 2011 and 2012 using parallel cases to determine trends across time and changes in practice patterns in the management of non-Hodgkin’s lymphoma.
September 2012
46 pages
US Oncologist Survey: Optimizing Treatment for Advanced Lung Cancer
US$ 1,200.00
... to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment ... with adenocarcinoma Former light smoker whose cancer is EGFR positive Treatment decisions for advanced stages of cancer are difficult to track as information ...
April 2011
56 pages
US Oncologist Survey: Optimizing Treatment for Large Cell Lymphoma
US$ 500.00
... that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progressions reveal ... Barriers to optimal patient care Confidence in treatment Data has been synthesized to show all responses and direct quotes from the oncologists ...
April 2011
35 pages
US Oncologist Survey: Optimizing Treatment for Advanced Non-Hodgkin's Lymphoma
US$ 1,200.00
... . This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of specific patient types. Patient situations: Asymptomatic indolent lymphoma Elderly infirm patient with advanced follicular lymphoma Relapsed ...
April 2011
61 pages
Castration Resistant Prostate Cancer: Clinical Insights from a US Oncologists' Survey
US$ 500.00
... for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment and testing choices, factors ... are missing, directly from high-prescribing US oncologists on the treatment of patients with advanced prostate cancer. Treatment decisions for advanced stages ...
March 2011
24 pages
US Oncologist Survey: Optimizing Treatment for Advanced Prostate Cancer
US$ 1,200.00
... that unfold throughout the report, presented to 119 high-prescribing oncologists on Metastatic Clear Cell Renal Cell Cancer for their open ... , barriers to optimal care, and confidence in treatment. Patients include: Patient case scenarios that progressively unfold, presented to 154 oncologists in a survey for ...
March 2011
52 pages
Oncologist Survey: Optimizing Treatment for Advanced Renal Cell Cancer
US$ 500.00
Treatment decisions for advanced stages of renal cell cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening ...
February 2011
59 pages
US Oncologist Survey: Optimizing Treatment for Metastatic Breast Cancer
US$ 1,200.00
Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at ...
January 2011
59 pages
Triple Positive Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey
US$ 500.00
... the report, presented to 174 high-prescribing oncologists on Triple Positive Metastatic Breast Cancer for their open responses on clinical decisions. Patient ... the report, presented to 119 high-prescribing oncologists on Metastatic Clear Cell Renal Cell Cancer for their open responses on clinical decisions. ...
January 2011
30 pages
